<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263936</url>
  </required_header>
  <id_info>
    <org_study_id>T2016-003</org_study_id>
    <nct_id>NCT03263936</nct_id>
  </id_info>
  <brief_title>Epigenetic Reprogramming in Relapse/Refractory AML</brief_title>
  <official_title>Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutic Advances in Childhood Leukemia Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutic Advances in Childhood Leukemia Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study using decitabine and vorinostat before and during chemotherapy with
      fludarabine, cytarabine and G-CSF (FLAG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Decitabine is a demethylating agent and vorinostat is a HDAC inhibitor. The use of
      demethylating agents and HDAC inhibitors in combination have been previously shown to have
      synergistic effects in altering neoplastic pathways of cancer cells and be well tolerated in
      human clinical studies. With the ability of decitabine and vorinostat to alter the abnormal
      cellular pathways of leukemic blasts and essentially turn off anti-apoptotic proteins, the
      leukemia cells have become primed for cytotoxic cell kill via chemotherapeutic agents. This
      study will ask the question as to whether or not the combination of decitabine and vorinostat
      followed by chemotherapy is feasible and whether it can positively impact outcome in patients
      with relapsed or refractory acute myelogenous leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The dose of decitabine that can be safely given with vorinostat, fludarabine, high dose cytarabine and G-CSF (FLAG)</measure>
    <time_frame>during course 1, approx 5 weeks</time_frame>
    <description>The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the extent of hypomethylation of peripheral blood (PB) and bone marrow (BM) pre- and post- decitabine and vorinostat treatmen</measure>
    <time_frame>approx 8 weeks</time_frame>
    <description>LINE-1 methylation assay as a surrogate marker of global DNA methylation.
Direct Comprehensive DNA methylation analysis
Gene expression profiling to assess genetic changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the correlation between DNA methylation and gene expression pre- and post-treatment with decitabine and vorinostat.</measure>
    <time_frame>approx 8 weeks</time_frame>
    <description>To analyze the correlation between DNA methylation and gene expression pre- and post-treatment with decitabine and vorinostat using standard statistical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine peripheral blood mononuclear cells for immunophenotypic changes.</measure>
    <time_frame>approx 8 weeks</time_frame>
    <description>To examine peripheral blood mononuclear cells for immunophenotypic changes using peripheral blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze plasma for cytokine content.</measure>
    <time_frame>approx 8 weeks</time_frame>
    <description>To analyze plasma for cytokine content using plasma samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the correlation between biological changes and clinical response.</measure>
    <time_frame>approx 8 weeks</time_frame>
    <description>To analyze the correlation between biological changes and clinical response using standard statistical methods</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Age &lt;18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Zolinza, SAHA, suberoylanilide acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Given on days 5 until evidence of ANC recovery (&gt;500/µL)5µg/kg/dose IV or SQ (starting at hour 0)</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>G-CSF, neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10</description>
    <arm_group_label>Other</arm_group_label>
    <other_name>Cytosine arabinoside, Ara-C, Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients must be ≥ 1 and ≤25 years of age.

        Diagnosis:

        - Patients with AML must have ≥ 5% blasts (by morphology) in the bone marrow

          -  Patients may have CNS or other sites of extramedullary disease. No cranial irradiation
             is allowed during the protocol therapy.

          -  Patients with secondary AML are eligible

          -  Patients with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom
             syndrome) are excluded.

        Performance Level:

        - Karnofsky &gt;50% for patients &gt;16 years of age and Lansky &gt; 50% for patients ≤ 16 years of
        age (See Appendix II for Performance Scales)

        Prior therapy

        - Patients must have fully recovered from the acute toxic effects of all prior
        chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

          1. Phase 1

             - Any patient with AML in 1st or greater relapse, OR

             - Patients with AML failed to go into remission after first or greater relapse, OR

             - Patients with AML failed to go into remission from original diagnosis after two or
             more induction attempts.

          2. Cytoreduction with hydroxyurea - Hydroxyurea can be initiated and continued for up to
             24 hours prior to the start of decitabine/vorinostat. It is recommended to use
             hydroxyurea in patients with significant leukocytosis (WBC &gt;50,000/L) to control blast
             count before initiation of systemic protocol therapy.

          3. Patients who relapsed while they are receiving cytotoxic therapy

             - At least 14 days must have elapsed since the completion of the cytotoxic
             therapy,except Intrathecal chemotherapy.

             Hematopoietic stem cell transplant (HSCT):

             - Patients who have experienced their relapse after a HSCT are eligible, provided they
             have no evidence of acute or chronic Graft-versus-Host Disease (GVHD).

             Hematopoietic growth factors:

             - It must have been at least 7 days since the completion of therapy with GCSF or other
             growth factors at the time of enrollment. It must have been at least 14 days since the
             completion of therapy with pegfilgrastim (Neulasta ®)

             Biologic (anti-neoplastic agent):

             -At least 7 days after the last dose of a biologic agent. For agents that have known
             adverse events occurring beyond 7 days after administration, this period must be
             extended beyond the time during which adverse events are known to occur. The duration
             of this interval must be discussed with the study chair.

             Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after
             the last dose of monoclonal antibody (i.e. Gemtuzumab = 36 days)

             Immunotherapy: At least 42 days after the completion of any time of immunotherapy,
             e.g. tumor vaccines or CAR T-cell therapy.

             XRT: Cranio or craniospinal XRT is prohibited during protocol therapy. No washout
             period is necessary for radiation given to non-CNS chloromas; &gt;90 days must have
             elapsed if prior TBI, cranio or craniospinal XRT.

             Prior Demethylating and/or HDAC Inhibitor Therapy: Patients who have received prior
             DNMTi (e.g. decitabine) and/or HDACi (e.g. vorinostat) therapy are eligible to
             participate in this Phase 1 study. At least 7 days must have passed from prior DNMTi
             or HDACi as a washout period.

             Renal and hepatic function: Patients must have adequate renal and hepatic functions as
             indicated by the following laboratory values:

             A. Adequate renal function defined as: Patient must have a calculated creatinine
             clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine based on
             age/gender.

             B. Adequate Liver Function Defined as: Direct bilirubin &lt; 1.5 x upper limit of normal
             (ULN) for age or normal, AND alanine transaminase (ALT) &lt; 5 x ULN for age. The hepatic
             requirements are waived for patients with known or suspected liver involvement by
             leukemia. This must be reviewed by and approved by the study chair or vice chair.

             Adequate Cardiac Function Defined as: Shortening fraction of ≥ 27% by echocardiogram,
             OR ejection fraction of ≥ 50% by radionuclide angiogram (MUGA).

             Reproductive Function A. Female patients of childbearing potential must have a
             negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.

             B. Female patients with infants must agree not to breastfeed their infants while on
             this study.

             C. Male and female patients of child-bearing potential must agree to use an effective
             method of contraception approved by the investigator during the study and for a
             minimum of 6 months after study treatment.

             Exclusion Criteria:

             -No NG or G-Tube administration of Vorinostat is allowed. Capsule must be swallowed
             whole or given as oral suspension.

             -They are currently receiving other investigational drugs.

             -There is a plan to administer non-protocol chemotherapy, radiation therapy, or
             immunotherapy during the study period.

             -They have significant concurrent disease, illness, psychiatric disorder or social
             issue that would compromise patient safety or compliance, interfere with consent,
             study participation, follow up, or interpretation of study results.

             -They have a known allergy to any of the drugs used in the study.

             -Patients with Down syndrome are excluded.

               -  Patients with DNA fragility syndromes are excluded (e.g. Fanconi Anemia, Bloom
                  Syndrome)

               -  They are receiving valproic acid (VPA) therapy.

               -  Patients with Acute Promyelocytic Leukemia (APL, APML) are excluded

               -  Patients with documented active and uncontrolled infection at the time of study
                  entry are not eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ellynore A Florendo, M.S.</last_name>
    <phone>323-361-3022</phone>
    <email>eflorendo@chla.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Shin-Kashiyama, J.D.</last_name>
    <email>eshinkashiyama@chla.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hart</last_name>
      <email>nhart@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul S. Gaynon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Harned, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Van Thu Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF School of Medicine</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Hermiston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>, RN</last_name>
    </contact>
    <investigator>
      <last_name>Lia Gore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Reuven Schore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julio Barredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gregory Hale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Todd Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nobuko Hijiya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pat Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrick Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Pediatric Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nirali Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lewis Silverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raymond Hutchinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Mott Children's Hospital, Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raymond J Hutchinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yoav Messinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elizabeth Raetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Luisa Sulis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joel Kaplan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maureen O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robyn Dennis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susan Rheingold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kenneth Heym, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center, Baylor</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric S Schafer, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elizabeth Raetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Todd Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mike Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Ziegler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luciano Dalla-Pozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead, NSW</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kirk Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jim Whitlock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sainte Justine University Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Henrique Bittencourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapse</keyword>
  <keyword>Myelogenous</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Refractory</keyword>
  <keyword>Acute</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

